249 related articles for article (PubMed ID: 25659157)
1. Volumetric analysis of the hypothalamus in Huntington Disease using 3T MRI: the IMAGE-HD Study.
Gabery S; Georgiou-Karistianis N; Lundh SH; Cheong RY; Churchyard A; Chua P; Stout JC; Egan GF; Kirik D; Petersén Å
PLoS One; 2015; 10(2):e0117593. PubMed ID: 25659157
[TBL] [Abstract][Full Text] [Related]
2. Early changes in the hypothalamic region in prodromal Huntington disease revealed by MRI analysis.
Soneson C; Fontes M; Zhou Y; Denisov V; Paulsen JS; Kirik D; Petersén A;
Neurobiol Dis; 2010 Dec; 40(3):531-43. PubMed ID: 20682340
[TBL] [Abstract][Full Text] [Related]
3. Multidisciplinary rehabilitation reduces hypothalamic grey matter volume loss in individuals with preclinical Huntington's disease: A nine-month pilot study.
Bartlett DM; Dominguez D JF; Lazar AS; Kordsachia CC; Rankin TJ; Lo J; Govus AD; Power BD; Lampit A; Eastwood PR; Ziman MR; Cruickshank TM
J Neurol Sci; 2020 Jan; 408():116522. PubMed ID: 31665619
[TBL] [Abstract][Full Text] [Related]
4. Hypothalamic and Limbic System Changes in Huntington's Disease.
Petersén A; Gabery S
J Huntingtons Dis; 2012; 1(1):5-16. PubMed ID: 25063186
[TBL] [Abstract][Full Text] [Related]
5. The phosphodiesterase 10 positron emission tomography tracer, [18F]MNI-659, as a novel biomarker for early Huntington disease.
Russell DS; Barret O; Jennings DL; Friedman JH; Tamagnan GD; Thomae D; Alagille D; Morley TJ; Papin C; Papapetropoulos S; Waterhouse RN; Seibyl JP; Marek KL
JAMA Neurol; 2014 Dec; 71(12):1520-8. PubMed ID: 25322077
[TBL] [Abstract][Full Text] [Related]
6. Early white matter pathology in the fornix of the limbic system in Huntington disease.
Gabery S; Kwa JE; Cheong RY; Baldo B; Ferrari Bardile C; Tan B; McLean C; Georgiou-Karistianis N; Poudel GR; Halliday G; Pouladi MA; Petersén Å
Acta Neuropathol; 2021 Nov; 142(5):791-806. PubMed ID: 34448021
[TBL] [Abstract][Full Text] [Related]
7. Selective perforant-pathway atrophy in Huntington disease: MRI analysis of hippocampal subfields.
Wibawa P; Walterfang M; Malpas CB; Glikmann-Johnston Y; Poudel G; Razi A; Hannan AJ; Velakoulis D; Georgiou-Karistianis N
Eur J Neurol; 2023 Sep; 30(9):2650-2660. PubMed ID: 37306313
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal diffusion changes in prodromal and early HD: Evidence of white-matter tract deterioration.
Shaffer JJ; Ghayoor A; Long JD; Kim RE; Lourens S; O'Donnell LJ; Westin CF; Rathi Y; Magnotta V; Paulsen JS; Johnson HJ
Hum Brain Mapp; 2017 Mar; 38(3):1460-1477. PubMed ID: 28045213
[TBL] [Abstract][Full Text] [Related]
9. Mapping the order and pattern of brain structural MRI changes using change-point analysis in premanifest Huntington's disease.
Wu D; Faria AV; Younes L; Mori S; Brown T; Johnson H; Paulsen JS; Ross CA; Miller MI;
Hum Brain Mapp; 2017 Oct; 38(10):5035-5050. PubMed ID: 28657159
[TBL] [Abstract][Full Text] [Related]
10. Structural brain correlates of dementia in Huntington's disease.
Martinez-Horta S; Sampedro F; Horta-Barba A; Perez-Perez J; Pagonabarraga J; Gomez-Anson B; Kulisevsky J
Neuroimage Clin; 2020; 28():102415. PubMed ID: 32979842
[TBL] [Abstract][Full Text] [Related]
11. Changes in key hypothalamic neuropeptide populations in Huntington disease revealed by neuropathological analyses.
Gabery S; Murphy K; Schultz K; Loy CT; McCusker E; Kirik D; Halliday G; Petersén A
Acta Neuropathol; 2010 Dec; 120(6):777-88. PubMed ID: 20821223
[TBL] [Abstract][Full Text] [Related]
12. Hypothalamic and neuroendocrine changes in Huntington's disease.
Hult S; Schultz K; Soylu R; Petersén A
Curr Drug Targets; 2010 Oct; 11(10):1237-49. PubMed ID: 20594177
[TBL] [Abstract][Full Text] [Related]
13. Brain structure in juvenile-onset Huntington disease.
Tereshchenko A; Magnotta V; Epping E; Mathews K; Espe-Pfeifer P; Martin E; Dawson J; Duan W; Nopoulos P
Neurology; 2019 Apr; 92(17):e1939-e1947. PubMed ID: 30971481
[TBL] [Abstract][Full Text] [Related]
14. Multi-modal neuroimaging in premanifest and early Huntington's disease: 18 month longitudinal data from the IMAGE-HD study.
Domínguez D JF; Egan GF; Gray MA; Poudel GR; Churchyard A; Chua P; Stout JC; Georgiou-Karistianis N
PLoS One; 2013; 8(9):e74131. PubMed ID: 24066104
[TBL] [Abstract][Full Text] [Related]
15. Hypothalamic-endocrine aspects in Huntington's disease.
Petersén A; Björkqvist M
Eur J Neurosci; 2006 Aug; 24(4):961-7. PubMed ID: 16925587
[TBL] [Abstract][Full Text] [Related]
16. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data.
Tabrizi SJ; Scahill RI; Owen G; Durr A; Leavitt BR; Roos RA; Borowsky B; Landwehrmeyer B; Frost C; Johnson H; Craufurd D; Reilmann R; Stout JC; Langbehn DR;
Lancet Neurol; 2013 Jul; 12(7):637-49. PubMed ID: 23664844
[TBL] [Abstract][Full Text] [Related]
17. Hypothalamic involvement in Huntington's disease: an in vivo PET study.
Politis M; Pavese N; Tai YF; Tabrizi SJ; Barker RA; Piccini P
Brain; 2008 Nov; 131(Pt 11):2860-9. PubMed ID: 18829696
[TBL] [Abstract][Full Text] [Related]
18. Abnormal synchrony of resting state networks in premanifest and symptomatic Huntington disease: the IMAGE-HD study.
Poudel GR; Egan GF; Churchyard A; Chua P; Stout JC; Georgiou-Karistianis N
J Psychiatry Neurosci; 2014 Mar; 39(2):87-96. PubMed ID: 24083458
[TBL] [Abstract][Full Text] [Related]
19. Striatal morphology and neurocognitive dysfunction in Huntington disease: The IMAGE-HD study.
Wilkes FA; Abaryan Z; Ching CRK; Gutman BA; Madsen SK; Walterfang M; Velakoulis D; Stout JC; Chua P; Egan GF; Thompson PM; Looi JCL; Georgiou-Karistianis N
Psychiatry Res Neuroimaging; 2019 Sep; 291():1-8. PubMed ID: 31330407
[TBL] [Abstract][Full Text] [Related]
20. Hybrid 2-[18F] FDG PET/MRI in premanifest Huntington's disease gene-expansion carriers: The significance of partial volume correction.
Hellem MNN; Vinther-Jensen T; Anderberg L; Budtz-Jørgensen E; Hjermind LE; Larsen VA; Nielsen JE; Law I
PLoS One; 2021; 16(6):e0252683. PubMed ID: 34115782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
